These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9401086)

  • 1. Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP.
    Wierenga PK; Dillingh JH; Konings AW
    Br J Haematol; 1997 Dec; 99(3):692-8. PubMed ID: 9401086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3).
    Wierenga PK; Setroikromo R; Vellenga E; Kampinga HH
    Br J Haematol; 2000 Dec; 111(4):1145-52. PubMed ID: 11167754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression.
    Wierenga PK; Brenner MK; Konings AW
    Bone Marrow Transplant; 1998 Jan; 21(1):73-8. PubMed ID: 9486498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.
    Wierenga PK; Setroikromo R; Kamps G; Kampinga HH; Vellenga E
    Exp Hematol; 2003 May; 31(5):421-7. PubMed ID: 12763141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia.
    Herrmann RP; O'Reilly J; Meyer BF; Lazzaro G
    Bone Marrow Transplant; 1992 Sep; 10(3):293-5. PubMed ID: 1358379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and characteristics of murine leukaemic and normal stem cells after hyperthermia: a murine model for human bone marrow purging.
    Gidáli J; Szamosvölgyi S; Fehér I; Kovács P
    Leuk Res; 1990; 14(5):453-7. PubMed ID: 2345468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide.
    Comte L; Lorgeot V; Bignon J; Volkov L; Dupuis F; Wdzieczak-Bakala J; Praloran V
    Eur J Clin Invest; 1998 Oct; 28(10):856-63. PubMed ID: 9793000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor.
    Wierenga PK; Setroikromo R; Kamps G; Kampinga HH; Vellenga E
    J Hematother Stem Cell Res; 2002 Jun; 11(3):523-32. PubMed ID: 12183837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors.
    Massé A; Ramirez LH; Bindoula G; Grillon C; Wdzieczak-Bakala J; Raddassi K; Deschamps de Paillette E; Mencia-Huerta JM; Koscielny S; Potier P; Sainteny F; Carde P
    Blood; 1998 Jan; 91(2):441-9. PubMed ID: 9427696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
    Wiley JM; Yeager AM
    Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
    Kühl JS; Sikic BI; Blume KG; Chao NJ
    Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro purging of clonogenic leukemic cells from human bone marrow by heat: simulation experiments for autologous bone marrow transplantation.
    Moriyama Y; Hashimoto S; Goto T; Furukawa T; Kishi K; Takahashi M; Shibata A
    Leuk Res; 1992 Oct; 16(10):973-7. PubMed ID: 1405711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermia potentiates the activity of immunotoxin conjugates against common acute lymphoblastic leukaemia cells in vitro.
    Herrmann RP; Pelham JM; Raphael CL; Meyer BF; Davis RE
    Ann N Y Acad Sci; 1987; 511():428-35. PubMed ID: 2964219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of hyperthermia in bone marrow purging of breast cancer.
    Ingram SS; Samulski T; Dodge R; Prosnitz LR; Peters P; Vredenburgh J
    Int J Hyperthermia; 1996; 12(1):21-9. PubMed ID: 8676004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
    Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
    Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-interferon broadens the difference between surviving fractions of normal and leukemic progenitor cells in vitro by heat: its application to marrow purging.
    Moriyama Y; Goto T; Nikkuni K; Aoki A; Furukawa T; Narita M; Koyama S; Kishi K; Takahashi M; Shibata A
    Bone Marrow Transplant; 1991 Oct; 8(4):301-5. PubMed ID: 1756327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells.
    Carlo-Stella C; Regazzi E; Garau D; Mangoni L; Rizzo MT; Bonati A; Dotti G; Almici C; Rizzoli V
    Br J Haematol; 1996 Jun; 93(3):551-7. PubMed ID: 8652372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.